恩替卡韦联合水飞蓟宾治疗e抗原阳性慢性乙型肝炎45例  

Combination of entecavir and silybin for the treatment of e antigen-positive chronic hepatitis B: a report of 45 cases

作　　者：黄钟鸣[1] 沈文娟[1] 哈明昊[1] 黄蔚玲[1] 陈晓兰[1] 吴建秋[1] 单文艳[1] 

机构地区：[1]上海市第七人民医院感染性疾病科,上海200137

出　　处：《上海中医药杂志》2014年第4期46-47,共2页Shanghai Journal of Traditional Chinese Medicine

基　　金：上海市浦东新区卫生系统学科带头人培养计划项目(PWRd2011-06)

摘　　要：目的观察恩替卡韦联合水飞蓟宾治疗e抗原阳性慢性乙型肝炎的临床疗效。方法将90例e抗原阳性的慢性乙型肝炎患者随机分为治疗组和对照组,每组45例。对照组予恩替卡韦口服,治疗组予恩替卡韦联合水飞蓟宾口服。两组疗程均为6个月,观察ALT、HBeAg、HBV-DNA变化情况。结果治疗后,治疗组ALT复常率、HBeAg阴转率及HBV-DNA阴转率分别为97.8%、71.1%、88.8%,对照组分别为86.7%、48.9%、71.1%;组间治疗后比较,HBeAg阴转率、HBV-DNA阴转率差异有统计学意义(P<0.05),ALT复常率差异无统计学意义(P>0.05)。结论恩替卡韦联合水飞蓟宾能有效抑制HBV-DNA的复制,明显提高血清ALT复常率及e抗原阴转率。Objective To observe the clinical efficacy of entecavir and silybin in treating e antigen-positive chronic hepatitis B. Methods Ninety cases with e antigen-positive chronic hepatitis B （CHB） were randomized into treatment group and control group, with 45 cases in each group. The control group was treated with entecavir orally, and the treatment group was treated with entecavir and silybin orally, with the course of 6 months. We observed the changes of ALT, HBeAg and HBV-DNA. Results After 6 months treatment, the recovery rate of ALT, negative conversion rate of HBeAg and negative conversion rate of HBV-DNA in the treatment group was 97.8%, 71.1% and 88.8% respectively, and was 86.7%, 48.9% and 71.1% respectively in the control group ; after 6 months treatment, there were significant differences in negative conversion rates of HBeAg and HBV-DNA between the two groups （ P 〈 0.05 ）, but no significant difference was found in recovery rate of ALT （ P 〉 0.05 ）. Conclusion Combined entecavir and silybin can inhibit the duplication of HBV-DNA, improve the recovery rate of ALT and negative conversion rates of HBeAg effectively.

关 键 词：慢性乙型肝炎 E抗原阳性 恩替卡韦 水飞蓟宾 

分 类 号：R512.62[医药卫生—内科学]